AAAdam Abdullahi

Adam Abdullahi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adam Abdullahi has a total of 197 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    HIV-1 integrase inhibitor resistance in viraemic-treated individuals and baseline capsid diversity relevant to future lenacapavir therapy

    by Adam Abdullahi, Sophia Osawe, Haruna Wisso, Martin Edun, Grace Adebisi, Judith Arachie, Chinedu Ude, James Onyemata, Suleiman Yusuf Alhaji, Yusuf Bara Jibrin, et al.

    Background: Dolutegravir (DTG)-based antiretroviral therapy has been widely adopted across sub-Saharan Africa, yet resistance pathways in non-B HIV-1 subtypes remain poorly defined. As lenacapavir (LEN), a long-acting capsid inhibitor, is introduced for prevention and treatment, characterizing baseline capsid variation alongside emerging integrase resistance is increasingly important. Whether DTG resistance pathways coexist with known capsid resistance mutations in West African epidemics remains poorly described. Methods: We performed deep sequencing of 87 HIV-1 samples from adults (n = 47) and paediatric participants (n = 40) failing DTG-based antiretroviral therapy in Nigeria. Resistance mutations were interpreted using Stanford HIVdb and IAS-USA criteria, with resistance estimates based on gene- or drug-panel-specific denominators. Low-frequency variants were assessed at 2%, 5%, 10% and 20% read-frequency thresholds. Capsid mutations associated with LEN resistance were characterized, structurally mapped and compared to global sequence data. HIV-1 subtype and recombinant forms were assigned using COMET HIV-1 v2.4. Results: At consensus, predicted resistance to ≥1 integrase strand transfer inhibitor (INSTI) was detected in 13/50 integrase-genotypable participants (26.0%; 95% CI 15.9%–39.6%), including 5/50 with a major INSTI resistance mutation. Reduced predicted susceptibility specifically to DTG was present in 6/50 (12.0%; 95% CI 5.6%–23.8%). G118R was detected in 4/50 participants at consensus, while Q148H/K/R and N155H were absent. In exploratory deep-sequencing analysis, G118R was detected in 8/47 participants with sufficient codon-level coverage at the ≥20% read-frequency threshold. No known primary LEN resistance mutation was detected among 33 participants with complete coverage of all six primary resistance positions (0/33; 95% CI 0%–10.4%); T107A, a polymorphic capsid substitution of uncertain effect on LEN susceptibility, was detected in in 3/33 individuals where sequence could be evaluated. Conclusions: These findings demonstrate DTG resistance in both adult and paediatric participants with virological failure with G118R emerging as a prominent resistance pathway. No known primary LEN resistance mutation was detected in the assessable capsid sequences, although phenotypic susceptibility and clinical outcomes were not evaluated. These findings support continued surveillance of integrase and capsid resistance as long-acting antiretroviral strategies expand.

  • Open Access

    Longitudinal Outcomes of Dolutegravir-Based Antiretroviral Therapy in a Large Nigerian Programmatic HIV-1 Cohort, 2017–2019

    by Adam Abdullahi, Edun Martin, Asare Kwabena, Haruna Wisso Abdullahi, Ibrahim Musa Kida, Sophia Osawe, James Onyemata, Sani H Aliyu, Manhattan Charurat, Fatima-Murtala Ibrahim, et al.

    In a retrospective Nigerian cohort of 33 982 people with HIV-1 initiating or switching to tenofovir, lamivudine, and dolutegravir, virological suppression reached 80%–82% among participants with available viral load data and 63%–65% by intention-to-treat analysis. Suppression was higher among switchers, while age and gender predicted suppression.

  • Open Access

    A simplified antigen-based serological algorithm accurately classifies MPXV exposure and vaccination status

    by Adam Abdullahi, Grace Adebisis, Haruna Wisso, Sophia Osawe, Beate Kampmann, Alash'LE Abimiku, Ravindra K Gupta

    Reliable serological tools are needed to measure mpox virus (MPXV) exposure, evaluate vaccine-induced immunity, and support population-level surveillance. Using a previously established six-antigen serological reference framework, in which seropositivity was defined as reactivity to ≥4 of 6 MPXV antigens, we evaluated the diagnostic performance of individual antigens and all 15 pairwise combinations. B6R demonstrated the highest overall individual discriminatory performance, whereas A35R showed maximal sensitivity and M1R the highest specificity. The A35R+B6R combination most closely approximated the full multiplex assay (AUC 0.93), supporting simplified, scalable MPXV serological assays for surveillance and vaccine evaluation.

  • Open Access

    SARS-CoV-2 Omicron infection reveals imprinted antibody responses in the absence of vaccination

    by Adam Abdullahi, Rebecca B. Morse, Mark Tsz Kin Cheng, Fehintola Ige, James Onyemata, Martin Edun, Anezka Kramna, Benjamin Sievers, Sam Turner, Haruna Wisso, et al.


  • Open Access

    Sero-genomic evidence for occult mpox exposure in healthy Nigerian adults

    by Adam Abdullahi, Ifeanyi Omah, Reshma Kassanjee, Fehintola Ige, Martin Edun, Sophia Osawe, Catherine K. Koofhethile, Haruna Wisso, Ezenwa James Onyemata, Edyth Parker, et al.

    The 2022 multi-country mpox (formerly monkeypox) outbreak, driven by mpox virus (MPXV) Clade IIb poses renewed threat to global public health. The cessation of smallpox vaccination has created large immunologically naïve cohorts, with uncertain implications for contemporary MPXV susceptibility. To assess whether residual vaccination-derived immunity influences exposure risk, we combine serological and phylodynamic analyses. Using a six-plex Luminex assay, we measure immunoglobulin G (IgG) binding to six MPXV antigens in 176 Nigerian adults comprising of 75 healthcare workers sampled in 2021 and 101 community volunteers sampled in 2023. At baseline, 24/176 (13.6%) were MPXV seropositive, predominantly born before 1980. Magnitude-breadth analysis scores were two-fold higher in pre-1980 cohort relative to post-1980 cohort. In 153 participants with follow-up samples (median 9 months), 5/153 (3%) showed evidence of exposure, with ≥2-fold increases in magnitude-breadth scores and antigen-specific responses against ≥4/6 antigens without reported clinical illness. Antigen-specific responses were strongest to B6R (11-fold), followed by M1R and A35R, with marked individual-level heterogeneity. Complementary phylodynamic reconstruction of 105 Nigerian MPXV genomes identified sporadic transmission against frequent dead-end infections. Together, these data show that residual smallpox immunity continues to shape mpox transmission and asymptomatic exposure contributes to under-detected spread, informing surveillance and targeted vaccination strategies.


  • Open Access

    Factors Influencing COVID-19 Vaccine Acceptance and Hesitancy among Pregnant Women in Nigeria

    by Sophia Osawe, Yusuff Olasunkanmi, Mobolaji Modinat Salawu, Omowumi Omolola Okedare, Felicia Okolo, Sikiratu Babamale, James Onyemata, Tolulope Adenekan, Adam Abdullahi, Alash'Le Abimiku

    Background: Vaccine hesitancy has been a serious public health concern. Pregnant women are at higher risk of developing complications related to COVID-19 infections and other infectious diseases. These complications can lead to poor outcomes for infants. This study assessed the level of hesitancy of COVID-19 vaccination among pregnant women in Nigeria. Method: A hospital-based cross-sectional study was conducted among 104 pregnant women at the Plateau State Specialist Hospital antenatal clinic. A semi-structured data collection tool of 15 items was used to assess participants’ COVID-19 vaccine hesitancy, with scores below the mean indicating hesitancy. Data were collected and managed using the Research Electronic Data Capture (REDCap). Descriptive analyses and binary logistic regression were done using Stata MP 18, and a significant p-value was set at <0.05. Results: The mean age of the participants was 30.3 (SD 6.3) years, with less than half (49%) falling within the 25-34 age group. Majority (96.2%) of the participants were married, resided in the urban area (84.6%) and were employed (64.4%). More than half of the participants had more than one child (72.1%), were healthy (55.8%) and had no family members or friends who had taken the COVID-19 vaccine (70.2%). About 71% of the participants had a positive perception of the COVID-19 vaccine. The overall mean score for vaccine hesitancy among participants was 3.0 (S.D 1.6), with 57.7% hesitating to the COVID-19 vaccine. Participants with more than one child (aOR = 3.31, 95%CI=1.17-9.42), in healthy condition (aOR = 3.95, 95%CI=1.55-10.07), had family and friends who had received COVID-19 vaccine (aOR = 3.27, 95%CI=1.07-10.00) and Negative perception on COVID-19 vaccine (aOR = 4.16, 95%CI=1.05-16.57) had more likelihood to the hesitancy of COVID-19 vaccine. Conclusion: Nearly three out of five pregnant women in our study expressed COVID-19 vaccine hesitancy. Pregnant women were more likely to be hesitant to COVD-19 vaccines if the felt their health was good and had a family member that had received a COVID-19 shot. Public health efforts and education campaigns for pregnant women are needed to change their perception patterns in promoting vaccination uptake and inclusion in vaccine trials.

  • Open Access

    Knowledge, perceptions and acceptance of COVID-19 Vaccine in Plateau States, Nigeria: A Qualitative Study

    by Sophia Osawe, Sussan Israel-Isah, Timothy Adejoh, Tunde A. Alabi, Felicia Okolo, Sikiratu Babamale, Adam Abdullahi, Alash’le Abimiku

    Introduction and Objectives Knowledge, perceptions, and acceptance of vaccines play a role in evaluating the progress of past immunization programs and planning for future pandemics. The study assessed the knowledge, perceptions, and acceptance of COVID-19 vaccines among pregnant women, HCWs, and policymakers in Nigeria and identified the barriers and enablers to the uptake of COVID-19 vaccines and future ones. Methods The study adopted qualitative methods of qualitative collection, comprising focus group discussion (FGD) with pregnant women-who were HIV positive and negative- and key informant interviews (KII) with healthcare workers (HCWs) and policymakers in Plateau State, Nigeria. The sample comprised forty pregnant women, five HCWs and five policymakers. Data was managed using Dedoose (version 9.0) and analyzed thematically. Results Although all sub-groups acknowledged the importance of vaccination, COVID-19 vaccine hesitancy was identified amongst a significant proportion of pregnant women. This was because of safety concerns, misinformation and fear of side effects. HCWs were identified as key influencers of vaccine acceptance during pregnancy. Also, family and friends, personal beliefs, and awareness were found to be influencers of vaccination, while religious and cultural beliefs were identified as barriers. Policymakers and HCWs believe that there is a need for education and awareness to address misinformation and improve the trust in vaccine safety and the health system among pregnant women. Conclusion The participants were knowledgeable of vaccines. However, pregnant women expressed skepticism about the safety of the COVID-19 vaccines. Thus, addressing misinformation through public health awareness programs is important while leveraging the influence of the health workforce, community, and religious leaders in promoting vaccine acceptance.

  • Open Access

    Legacy immunity from prior smallpox vaccination and serological evidence of asymptomatic mpox transmission in a West African population

    by Adam Abdullahi, Ifeanyi Omah, Reshma Kassanjee, Sophia Osawe, Martin Edun, Fehintola Ige, Haruna Wisso, Edyth Parker, Onikepe Folarin, Aniekwe M. Isaac, et al.

    The 2022 multi-country mpox outbreak, driven by MPXV Clade IIb has spread globally to over 100 countries, posing a new threat to global public health. Smallpox vaccination was discontinued in 1980 following global elimination with recent reports demonstrating evidence of asymptomatic infections particularly in individuals unlikely to have received a smallpox vaccine. To determine whether residual vaccination-derived immunity still shapes infection risk and to characterise population level burden of covert and asymptomatic transmission in a West African population, we combined serological analysis with phylogenetic analysis. We first quantified IgG binding to six MPXV antigens (A29L, A35R, B6R, D6L, H3L and M1R) in 176 Nigerian adults comprising of 75 healthcare workers sampled in 2021 and 101 community volunteers sampled in 2023 using a six-plex Luminex assay. Using a stringent ≥4-antigen reactivity threshold, at baseline, 24/176 (13.6%) participants met definition of MPXV seropositivity likely due to previous vaccination. Most participants with MPXV seropositivity were born before 1980, suggestive of residual smallpox immunity. Magnitude-breadth analysis scores were 2-fold higher in pre-1980 cohort relative to post-1980 cohort. In a subset of individuals (n=153) with follow-up samples over a median of 9 months, 5/153 (3%) showed evidence of silent asymptomatic exposure determined by antibody boosting and characterised by ≥2-fold increases in both total magnitude and breadth scores antibodies against ≥ 4/6 tested antigens all of which were MPXV seronegative individuals at baseline and mostly males. Participant level kinetics showed B6-specific titres boosted most strongly (median 11-folds), followed by M1R (6.2-folds) and A35R (5.2-folds) highlighting their potential utility as sero-surveillance markers. Complementary phylogenetic reconstruction of 105 Nigerian MPXV genomes showed two epidemic phases with over-dispersion (k≈0.3), indicating transmission sustained by sporadic superspreading despite high degree of dead-end infections. Serological and genomic evidence points to sustained asymptomatic transmission of MPXV in healthy individuals in the African setting, thereby informing public health interventions.


  • Open Access

    Humoral responses to SARS-CoV-2 vaccine in vasculitis-related immune suppression

    by Kimia Kamelian, Benjamin Sievers, Michael Chen-Xu, Sam Turner, Mark Tsz Kin Cheng, Mazharul Altaf, Steven A. Kemp, Adam Abdullahi, Kata Csiba, Dami A. Collier, et al.

    Immune suppression poses a challenge to vaccine immunogenicity. We show that serum antibody neutralization against SARS-CoV-2 Omicron descendants was largely absent post-doses 1 and 2 in individuals with vasculitis treated with rituximab. Detectable and increasing neutralizing titers were observed post-doses 3 and 4, except for XBB. Rituximab in vasculitis exacerbates neutralization deficits over standard immunosuppressive therapy, although impairment resolves over time since dosing. We observed discordance between detectable IgG binding and neutralizing activity specifically in the context of rituximab use, with high proportions of individuals showing reasonable IgG titer but no neutralization. ADCC response was more frequently detectable compared to neutralization in the context of rituximab, indicating that a notable proportion of binding antibodies are non-neutralizing. Therefore, use of rituximab is associated with severe impairment in neutralization against Omicron descendants despite repeated vaccinations, with better preservation of non-neutralizing antibody activity.


  • Open Access

    Safety and Immunogenicity of Fractional Doses of COVID-19 Vaccines among Nigerian Adults- A Randomised Non-Inferiority trial

    by Salako Abideen Olurotimi, Musa Adesola Zaidat, Ige Fehintola Anthonia, Adam Abdullahi, Ayorinde Babatunde James, Ekama Sabdat, Odubela Oluwatosin, Idigbe Eugenia Ifeoma, Ajibaye Olusola, Altaf Mazharul, et al.

    The shortage of COVID-19 vaccines posed a significant challenge in optimal response to the COVID-19 pandemic. Fractional doses of vaccine with adequate immunogenic response and proven safety profile emerged as potential strategy to extend the limited vaccine doses. This study was aimed to evaluate the immunogenicity and safety of fractional doses of the ChadOx1, Ad26.COV2.S, and BNT162B2 vaccines among healthy Nigerian adults. A non-inferiority multi-site triple-blind clinical trial was undertaken in Nigeria. Healthy Nigerian adults (18-65 years) who met the inclusion criteria were enrolled in the study. Participants were block-randomized into three vaccine arms (ChadOx1 quarter, half, and full dose; Ad26.COV2.S: quarter, half and full dose; and BNT162B2: half and full dose) . Participants, clinical staff (clinicians and nurses) and laboratory personnel were blinded. The primary objective of the study was to evaluate non-inferiority in seroconversion rates, defined as geometric mean fold rise (GMFR) ≥ 2.5 in serum anti-spike IgG titre at 28 days post-vaccination by ELISA. Immunogenicity analysis included use of serum neutralization assays using pseudotyped virus bearing spike from Wu-1 and Omicron variants. A total of 1891 participants were enrolled between June 21, 2022, and January 25, 2023. 320 participants in the fractional dose group and 220 in the standard dose group completed follow-up and were included in the analysis. SARS-CoV-2 seropositivity at baseline was high, at 68% (365/539). Seroconversion (geometric mean fold rise) was comparable between standard and fractional doses. For ChAdOx1, 31% achieved ≥ 2.5 fold change increase in serum binding antibody in the standard dose arm (16/52), 28% in half dose (15/53), and 34% in quarter dose (18/53). For Ad26.COV2.S, the proportions were 27% (28/105) in standard dose, 32% (22/68) in half dose, and 30% (21/71) in quarter dose arms respectively. For BNT162N2, the proportions were 43% (27/63) in standard dose and 39% (29/75) in half dose. Subset analysis of binding and neutralization responses in (n=64) participants demonstrated high degree of of prior exposure to SARS-CoV-2 ancestral and Omicron lineage variants prior to vaccination. Serum neutralization responses showed ≥2-fold response to both full and fractional doses indicating immunogenic responses to the vaccine dosing regimens. There was no report of serious adverse events. Fractional vaccine doses showed potential to generate non-inferior immune responses compared to standard doses in the context of a population with high rate of previous exposure to SARS-CoV-2 infection. The three vaccines are safe and well tolerated. Fractional dose should be considered to boost herd immunity and prevent outbreaks of SARS-COV-2.